home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2794.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
53 lines
Document 2794
DOCN M94A2794
TI Efficacy of AM3 (glifofosfopeptical) as modulator of immunity in the
treatment of AIDS.
DT 9412
AU Ruiz Illescas R; Torrecillas L; Teran L; Centro Medico 20 de Noviembre,
Issste: Mexico, City.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0320). Unique
Identifier : AIDSLINE ICA10/94369781
AB OBJECTIVE: Investigate if AM3 has a cytoprotective effect by restoring
cytopenias induced by the use of AZT and other chemotherapy drugs, and
if AM3 improves response to treatment in AIDS associated neoplasm by
stimulating immune system. METHODS: 26 men with AIDS (26-40 years old,
median 33) in three groups; G1 = 9 patients with Kaposi Sarcoma mc
(KSmc) stage I-II; GII = 12 pts. KS stage III; GIII = 5 pts.: 3 pts. KS
stage IV and 2 with Immunoblastic Lymphoma. Treatment: AM3 3 grs/day;
AZT 500 mgs/day, in GII modified CHO was added and GIII had CHOP and
local RT additionally. The study was done august 1989-june 1993. Clinic
evaluation every 15 days; BCC;BC;LFT monthly;--lymphocytes population
every 3 months, cultures every 3 months and related to clinical data of
infection. Efficacy parameters: life quality, hematologic response,
lymphocytes population, number, type and length of infection, cancer
progression. RESULTS: G1 = KS lesions did not increase in number or
size, T4 lymphocytes without variation while this study was conducted (p
< 0.0312), no critical infections, no hospitalization, stage Karnofsky;
80-100. GII: KS lesions did not increase, T4 Lymphocytes decreased 20%
with respect baseline during chemotherapy (variance nT = 74) no critical
infections, no hospitalization, Karnofsky: 60-80; 20% variation of BCC
during chemotherapy with respect to baseline. GIII: KS lesions
progressed, tumoral lymphangitis decreased; T4 lymphocytes progressively
decreased, all patients died before one year. BCC decreases 34%.
CONCLUSIONS: AM3 is bone marrow cytoprotective, protects against
infections and in groups I and II lymphocytes T4 did not change (against
expected).
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS/IMMUNOLOGY/ *THERAPY
Adjuvants, Immunologic/PHARMACOLOGY/*THERAPEUTIC USE Adult
Antineoplastic Agents, Combined/ADVERSE EFFECTS/THERAPEUTIC USE
AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Biological
Response Modifiers/PHARMACOLOGY/*THERAPEUTIC USE Bone Marrow
Diseases/CHEMICALLY INDUCED/PREVENTION & CONTROL Calcium
Phosphates/PHARMACOLOGY/*THERAPEUTIC USE Comparative Study
Cyclophosphamide/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION &
DOSAGE Drug Evaluation Glycopeptides/PHARMACOLOGY/*THERAPEUTIC USE
Human Leukocyte Count Lymphoma, AIDS-Related/DRUG
THERAPY/ETIOLOGY/IMMUNOLOGY Lymphoma, Lymphoblastic/DRUG
THERAPY/ETIOLOGY/IMMUNOLOGY Male Prednisone/ADMINISTRATION & DOSAGE
Sarcoma, Kaposi's/DRUG THERAPY/ETIOLOGY/IMMUNOLOGY Treatment Outcome
T4 Lymphocytes Vincristine/ADMINISTRATION & DOSAGE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).